Stock RACA THES ACQU
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

THES ACQU Stock

Equities

RACA

US88339T1034

Biotechnology & Medical Research

Chart THES ACQU

Dynamic Chart

Latest news about THES ACQU

Therapeutics Acquisition Corp.(NasdaqCM:RACA) dropped from NASDAQ Composite Index CI
Point Biopharma Inc. completed the acquisition of Therapeutics Acquisition Corp. from Therapeutics Acquisition Holdings LLC and other shareholders in a reverse merger transaction. CI
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC CI
Therapeutics Acquisition : Point Biopharma Phase 3 Trial for Cancer Therapy Doses First Patient Group MT
Therapeutics Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Merck : Completes Pandion Therapeutics Acquisition MT
Therapeutics Acquisition : POINT Biopharma To Go Public Via SPAC Combination MT
Point Biopharma Inc. entered into a non-binding letter of intent to acquire Therapeutics Acquisition Corp. from Therapeutics Acquisition Holdings LLC and other shareholders in a reverse merger transaction. CI
Therapeutics Acquisition Corp.(NasdaqCM:RACA) added to NASDAQ Composite Index CI
Therapeutics Acquisition Corp. has completed an IPO in the amount of $118 million. CI
Certain Class B Common Stock of Therapeutics Acquisition Corp. are subject to a Lock-Up Agreement Ending on 5-JAN-2021. CI
Therapeutics Acquisition Corp. has filed an IPO in the amount of $100 million. CI
More news

Press releases THES ACQU

POINT BIOPHARMA GLOBAL INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Change in Shell Company Status, Financial Statements and Exhibits (form 8-K) AQ
THERAPEUTICS ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K) AQ
THERAPEUTICS ACQUISITION CORP. : Other Events (form 8-K) AQ
Therapeutics Acquisition : Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT. Special Meeting Scheduled for June 29, 2021 (Form 8-K) PU
THERAPEUTICS ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K) AQ
More press releases

Company Profile

POINT Biopharma Inc., formerly Therapeutics Acquisition Corp, is a late-stage clinical precision oncology company. The Company focuses on developing and commercializing radiopharmaceuticals for the treatment of cancer. Its pipeline programs include lutetium-177 and actinium-225. The Company's product candidates include PNT2002 and PNT2003 for the treatment of prostate cancer and neuroendocrine tumors. PNT2002 is a prostate-specific membrane antigen (PSMA), targeted radioligand is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 (177Lu-PSMA-I&T). PNT2003 is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. PNT2003 combines a somatostatin-specific radioligand DOTATATE with lutetium-177 (177Lu-DOTATATE).
Sector
Biotechnology & Medical Research
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.26% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 95.71B
ARGENX SE Stock argenx SE
+0.79% 22.02B
BIONTECH SE Stock BioNTech SE
-17.84% 20.9B
GENMAB A/S Stock Genmab A/S
-11.11% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.63% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.55% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.11% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RACA Stock